The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 16, 2018

Filed:

Feb. 27, 2014
Applicant:

Aquinox Pharmaceuticals (Canada) Inc., Vancouver, CA;

Inventors:

Lloyd F. Mackenzie, North Vancouver, CA;

Curtis Harwig, Vancouver, CA;

David Bogucki, Surrey, CA;

Jeffery R. Raymond, Vancouver, CA;

Jeremy D. Pettigrew, Burnaby, CA;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 473/34 (2006.01); C07D 207/335 (2006.01); C07D 207/06 (2006.01); C07D 213/38 (2006.01); C07D 231/12 (2006.01); C07D 249/08 (2006.01); C07D 233/60 (2006.01); C07D 209/08 (2006.01); C07D 317/46 (2006.01); C07D 295/096 (2006.01); C07D 213/64 (2006.01); C07D 239/34 (2006.01); C07D 241/18 (2006.01); C07C 279/08 (2006.01); C07C 215/42 (2006.01); C07C 233/23 (2006.01); C07C 311/04 (2006.01); C07C 225/10 (2006.01); C07C 233/74 (2006.01); C07C 255/31 (2006.01); C07C 275/24 (2006.01);
U.S. Cl.
CPC ...
C07D 473/34 (2013.01); C07C 215/42 (2013.01); C07C 225/10 (2013.01); C07C 233/23 (2013.01); C07C 233/74 (2013.01); C07C 255/31 (2013.01); C07C 275/24 (2013.01); C07C 279/08 (2013.01); C07C 311/04 (2013.01); C07D 207/06 (2013.01); C07D 207/335 (2013.01); C07D 209/08 (2013.01); C07D 213/38 (2013.01); C07D 213/64 (2013.01); C07D 231/12 (2013.01); C07D 233/60 (2013.01); C07D 239/34 (2013.01); C07D 241/18 (2013.01); C07D 249/08 (2013.01); C07D 295/096 (2013.01); C07D 317/46 (2013.01);
Abstract

Compounds of formula (I): where R, R, R, R, R, R, Rand Rare defined herein, or stereoisomers or pharmaceutically acceptable salts thereof, are described herein. Such compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.


Find Patent Forward Citations

Loading…